S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)
S&P 500   4,581.88 (+0.32%)
DOW   36,241.00 (+0.32%)
QQQ   387.86 (+0.15%)
AAPL   192.73 (-0.36%)
MSFT   370.75 (-0.48%)
META   319.36 (+0.34%)
GOOGL   131.36 (+0.28%)
AMZN   145.65 (-0.84%)
TSLA   244.50 (+2.42%)
NVDA   466.99 (+0.29%)
NIO   7.98 (+7.40%)
BABA   72.65 (+0.37%)
AMD   120.65 (+1.92%)
T   17.21 (-0.06%)
F   10.85 (+2.36%)
MU   74.26 (+0.77%)
CGC   0.72 (+7.45%)
GE   121.76 (+1.27%)
DIS   91.48 (+0.76%)
AMC   7.12 (+1.42%)
PFE   29.25 (+0.55%)
PYPL   59.02 (+1.90%)
XOM   100.32 (-0.12%)

CONMED Stock Price, News & Analysis (NYSE:CNMD)

$109.36
+0.91 (+0.84%)
(As of 10:09 AM ET)
Compare
Today's Range
$108.68
$109.65
50-Day Range
$91.30
$111.51
52-Week Range
$82.97
$138.47
Volume
15,386 shs
Average Volume
375,193 shs
Market Capitalization
$3.36 billion
P/E Ratio
59.11
Dividend Yield
0.73%
Price Target
$126.17

CONMED MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
16.3% Upside
$126.17 Price Target
Short Interest
Bearish
15.35% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-0.74
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$337,488 Sold Last Quarter
Proj. Earnings Growth
26.29%
From $3.50 to $4.42 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.03 out of 5 stars

Medical Sector

459th out of 948 stocks

Medical Devices Industry

10th out of 17 stocks


CNMD stock logo

About CONMED Stock (NYSE:CNMD)

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CNMD Stock Price History

CNMD Stock News Headlines

CONMED declares $0.20 dividend
Analyzing CONMED (NYSE:CNMD) and NeurAxis (NASDAQ:NRXS)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
The Conmed Corp (CNMD) Company: A Short SWOT Analysis
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
CNMD or ALGN: Which Is the Better Value Stock Right Now?
Conmed Corp. Q3 Profit Decreases, but beats estimates
Conmed: Q3 Earnings Snapshot
Conmed Corp (CNMD) Announces Q3 2023 Financial Results
See More Headlines
Receive CNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CONMED and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/5 Dividend
9/14/2023
Dividend Payable
10/05/2023
Last Earnings
10/25/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/01/2024

Industry, Sector and Symbol

Industry
Medical Devices
Sub-Industry
N/A
Sector
Medical
Employees
4,100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$126.17
High Stock Price Target
$141.00
Low Stock Price Target
$107.00
Potential Upside/Downside
+16.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-80,580,000.00
Pretax Margin
2.53%

Debt

Sales & Book Value

Annual Sales
$1.05 billion
Cash Flow
$5.17 per share
Book Value
$24.46 per share

Miscellaneous

Free Float
28,415,000
Market Cap
$3.34 billion
Optionable
Optionable
Beta
1.36
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report














CNMD Stock Analysis - Frequently Asked Questions

Should I buy or sell CONMED stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CONMED in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CNMD shares.
View CNMD analyst ratings
or view top-rated stocks.

What is CONMED's stock price target for 2024?

6 brokers have issued twelve-month target prices for CONMED's stock. Their CNMD share price targets range from $107.00 to $141.00. On average, they expect the company's stock price to reach $126.17 in the next year. This suggests a possible upside of 16.3% from the stock's current price.
View analysts price targets for CNMD
or view top-rated stocks among Wall Street analysts.

How have CNMD shares performed in 2023?

CONMED's stock was trading at $88.64 on January 1st, 2023. Since then, CNMD shares have increased by 22.4% and is now trading at $108.46.
View the best growth stocks for 2023 here
.

Are investors shorting CONMED?

CONMED saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 4,720,000 shares, an increase of 7.8% from the October 31st total of 4,380,000 shares. Based on an average daily volume of 359,400 shares, the short-interest ratio is presently 13.1 days.
View CONMED's Short Interest
.

When is CONMED's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 1st 2024.
View our CNMD earnings forecast
.

How were CONMED's earnings last quarter?

CONMED Co. (NYSE:CNMD) posted its earnings results on Wednesday, October, 25th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.07. The company had revenue of $304.58 million for the quarter, compared to analysts' expectations of $301.22 million. CONMED had a trailing twelve-month return on equity of 11.46% and a net margin of 4.96%.

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Thursday, August 10th. Shareholders of record on Friday, September 15th will be given a dividend of $0.20 per share on Thursday, October 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date is Thursday, September 14th.
Read our dividend analysis for CNMD
.

Is CONMED a good dividend stock?

CONMED (NYSE:CNMD) pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.73%. The dividend payout ratio is 43.24%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CNMD will have a dividend payout ratio of 18.10% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for CNMD.

What guidance has CONMED issued on next quarter's earnings?

CONMED updated its FY23 earnings guidance on Wednesday, October, 25th. The company provided EPS guidance of $3.45-3.55 for the period, compared to the consensus estimate of $3.48. The company issued revenue guidance of $1.24-1.26 billion, compared to the consensus revenue estimate of $1.25 billion.

Who are CONMED's major shareholders?

CONMED's stock is owned by many different retail and institutional investors. Top institutional investors include Earnest Partners LLC (7.37%), Loomis Sayles & Co. L P (2.57%), Principal Financial Group Inc. (1.99%), Bank of New York Mellon Corp (1.39%), Jennison Associates LLC (1.19%) and Northern Trust Corp (1.10%). Insiders that own company stock include Brian Concannon, Curt R Hartman, Daniel S Jonas, John D Ferrell, Johonna Marie Pelletier, Peter K Shagory, Stanley W Peters III, Todd W Garner and Todd W Garner.
View institutional ownership trends
.

How do I buy shares of CONMED?

Shares of CNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:CNMD) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -